+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Doxorubicin"

Soft Tissue Sarcoma Market Report 2025 - Product Thumbnail Image

Soft Tissue Sarcoma Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Sarcoma Drugs Market Report 2025 - Product Thumbnail Image

Sarcoma Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • March 2025
  • 450 Pages
  • Global
From
B-Cell Lymphoma - Pipeline Insight, 2025 - Product Thumbnail Image

B-Cell Lymphoma - Pipeline Insight, 2025

  • Clinical Trials
  • March 2025
  • 450 Pages
  • Global
From
Follicular Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Follicular Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 180 Pages
  • Global
From
Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 240 Pages
  • Global
From
Metastatic Urothelial Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Urothelial Carcinoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 150 Pages
  • Global
From
Soft Tissue Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Soft Tissue Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Desmoid Tumors - Pipeline Insight, 2024 - Product Thumbnail Image

Desmoid Tumors - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Clear Cell Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Clear Cell Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Kaposi's sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Kaposi's sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Synovial Sarcoma Pipeline Analysis Report - Product Thumbnail Image

Synovial Sarcoma Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Bladder Cancer Pipeline Analysis Report - Product Thumbnail Image

Bladder Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Liposomal Doxorubicin Market Report and Forecast 2024-2032 - Product Thumbnail Image

Liposomal Doxorubicin Market Report and Forecast 2024-2032

  • Report
  • October 2024
  • 200 Pages
  • Global
From
Ovarian Cancer Pipeline Analysis Report - Product Thumbnail Image

Ovarian Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Loading Indicator

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more